Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).
Consideration includes 700,000 common shares, $440,000 cash, 10.56 Bitcoin and 300 Ethereum to Orbit Capital.
Liora holds assets for LIGHT proton-based radiotherapy system acquired from Advanced Oncotherapy PLC.
Orbit retains 20% of Liora after terminating original royalty agreement and Series C Preferred exchange.
Agreement effective November 21, 2025, executed March 6, 2026 to unify multiple transaction documents.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.